CRISPR Therapeutics AG Files Q1 2025 10-Q
Ticker: CRSP · Form: 10-Q · Filed: May 6, 2025 · CIK: 1674416
Sentiment: neutral
Topics: 10-Q, biotech, collaboration, financials
Related Tickers: VRTX
TL;DR
CRISPR Therapeutics Q1 2025 10-Q filed. Updates on Vertex collab & financials.
AI Summary
CRISPR Therapeutics AG filed its 10-Q for the period ending March 31, 2025. The company's fiscal year ends on December 31st. Key financial data and business activities for the first quarter of 2025 are detailed in this report. The filing also references agreements with Vertex Pharmaceuticals Incorporated and its subsidiaries, including the Amended and Restated Vertex Joint Development and Commercialization Agreement.
Why It Matters
This filing provides investors with an update on CRISPR Therapeutics' financial health and operational progress for the first quarter of 2025, including details on their ongoing collaborations.
Risk Assessment
Risk Level: medium — As a biotechnology company, CRISPR Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 20250506 — Filing Date (Shows when the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- CRISPR Therapeutics AG (company) — Filer of the 10-Q
- Vertex Pharmaceuticals Incorporated (company) — Collaborator mentioned in agreements
- March 31, 2025 (date) — End of reporting period
- December 31 (date) — Fiscal year end
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 6, 2025.
What is CRISPR Therapeutics AG's fiscal year end?
CRISPR Therapeutics AG's fiscal year ends on December 31st.
Which company is mentioned in relation to joint development and commercialization agreements?
Vertex Pharmaceuticals Incorporated and its certain subsidiaries are mentioned in relation to joint development and commercialization agreements.
What is the SIC code for CRISPR Therapeutics AG?
The Standard Industrial Classification (SIC) code for CRISPR Therapeutics AG is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding CRISPR Therapeutics AG (CRSP).